Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Finding the Force of Mentorship: Self-awareness Through Direction - 2Doctors seek to understand why quitting antidepressants causes withdrawal for some
- 3Northern lights chances rise for Christmas as space weather remains unsettled
- 4How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- 5Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- Josh Duhamel's secret to the good life at 53? Wolverine peptides, ditching Hollywood and having another baby.
- Washington resident contracts bird flu, first human case in U.S. since February
- Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- Dozens killed as Angola flood death toll rises
- Pope Leo XIV calls for urgent climate action and says God’s creation is 'crying out'
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Europe picks companies to help build Argonaut moon lander
